InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,709.54
(
0.01%
)
US TECH 100
19,324.00
(
0.38%
)
Dow Jones
42,196.52
(
0.09%
)
Brent Oil
74.83
(
0.28%
)
Bitcoin
61,117.85
(
0.81%
)
Post# of 253268
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120524
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DFRAI post# 93018

Tuesday, 03/23/2010 2:20:59 PM

Tuesday, March 23, 2010 2:20:59 PM

Post# of 253268
genisi’s post about Copaxone’s pharmacokinetic properties is an almost verbatim copy of Teva’s talking points. This doesn’t necessarily mean that genisi’s post is wrong, but it’s not necessarily right either. What is patently clear is that Teva has been waging a vigorous propaganda campaign in the investment community with respect to the prospects for generic Copaxone.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up